Company Encyclopedia
View More
name
Phreesia
PHR.US
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers an appointment scheduling system for online appointments, reminders, and referral tracking and management; registration solutions to automate patient self-registration; revenue cycle solutions that provide insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network solutions to deliver clinically relevant content to patients. It deploys its platform in a range of modalities, including Phreesia Mobile, a patients’ mobile device; PhreesiaPads, a self-service intake tablets; Phreesia Dashboard, a web-based dashboard for healthcare services clients; and Arrivals Kiosks, which are on-site kiosks.
64.63 B
PHR.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
B
Health Care TechnologyIndustry
Industry Ranking4/44
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-1.87%D
    • Profit Margin-1.16%D
    • Gross Margin68.40%A
  • Growth ScoreB
    • Revenue YoY14.33%B
    • Net Profit YoY93.50%A
    • Total Assets YoY12.71%B
    • Net Assets YoY25.82%A
  • Cash ScoreD
    • Cash Flow Margin-8611.36%E
    • OCF YoY14.33%B
  • Operating ScoreA
    • Turnover1.16A
  • Debt ScoreB
    • Gearing Ratio24.36%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | Phreesia has fallen sharply consecutively, is short-term bottom-fishing capital ready to take action?

    Phreesia (PHR.US) has recently experienced multiple large declines, and is extremely oversold in the short term, with many bottom-fishing funds in the community starting to become active. Such oversold stocks are prone to emotional rebounds; is the short-term bottom-fishing opportunity right in front of us? First, let's look at the market. PHR has fallen more than expected over the past two weeks, showing a typical high beta stock's supplementary decline. During intraday trading, it directly pierced through a densely packed chip area from years past, with extreme bearish sentiment being released. Yesterday, a large order suddenly appeared at the lowest point of the day, and there was a significant increase in volume at the close, suggesting that funds may have already been lurking at the bottom. The community is generally bullish! Most veteran investors on PTT are preparing to "take a gamble," just waiting to see if the main force dares to take the initiative. The core of short-term bottom-fishing is actually to find reversal signals. Currently, the market shows a significant increase in volume and a rapid rise in turnover rate, indicating that the main force's accumulation actions are beginning to appear. What about the risks? They still exist. PHR's rebounds from overselling are generally extremely rapid, but false breakouts can also easily occur. In the short term, pay attention to the $36 level; as long as it stays above this, it is expected to welcome 2-3 bullish candles in a rebound trend, and the FOMO effect will amplify. However, if it falls below $34, caution is needed for another bottom test. It is recommended to enter and exit quickly when trading oversold rebounds, with targets set at moving averages or resistance zones. Once there is active buying from the main force during intraday trading, follow along but do not blindly chase. Long-term, still pay attention to whether the company's fundamental data shows any significant deterioration. Conclusion: PHR is extremely oversold and nearing its limit; a rebound window can be expected as volume expands. Short-term traders can focus on the next unusual movements from the main force

    Technical Forecast·
    US
    PHR
    +1.31%
    Technical Forecast·
    US
    PHR
    +1.31%

    Phreesia (NYSE:PHR) Upgraded at Zacks Research

    Zacks Research upgraded Phreesia (NYSE:PHR) from a "hold" to a "strong-buy" rating. Other analysts have also given positive ratings, with DA Davidson, Piper Sandler, and Mizuho raising their price targets. Phreesia reported better-than-expected earnings and revenue for the recent quarter. Insider trading activity showed minor decreases in stock ownership. Institutional investors have made significant changes to their positions in the stock. Phreesia provides SaaS-based software and payment platforms for the healthcare industry in the US and Canada.

    Market Beat·
    US
    PHR
    +1.31%
    Market Beat·
    US
    PHR
    +1.31%

    Why Phreesia stock plummeted by 23% today

    The company's third-quarter performance wasn't nearly as bad as the investor reaction to it might suggest.

    MSN·
    US
    PHR
    +1.31%
    MSN·
    US
    PHR
    +1.31%

    Phreesia’s Earnings Call: Growth and Strategic Moves

    Phreesia's Q3 earnings call highlighted robust revenue growth, strategic acquisitions, and positive financial metrics. Revenue increased by 13% to $120.3 million, with an adjusted EBITDA margin of 24%. The AccessOne acquisition expands Phreesia into provider financing and healthcare marketing. Positive net income of $4.3 million and strong cash flow were reported. Challenges in network solutions and acquisition debt management were noted. Forward guidance projects continued growth, with fiscal 2026 revenue between $479 million and $481 million, and fiscal 2027 revenue between $545 million and $559 million.

    Tip Ranks·
    US
    PHR
    +1.31%
    Tip Ranks·
    US
    PHR
    +1.31%

    Top 10 US Stock Losers (12.9)

    Phreesia(PHR) fell 23.31%, with a trading turnover 131.1 Million USD, and a year-to-date fell 38.7%. Gogo(GOGO) fell 19.11%, with a trading turnover 64.4 Million USD, and a year-to-date fell 32.5%. Dyne Therapeutics(DYN) fell 16.94%, with a trading turnover 120.6 Million USD, and a year-to-date fell 21.7%.

    Top Gainers & Losers·
    US
    PHR
    +1.31%
    US
    GOGO
    -9.91%
    US
    DYN
    -0.77%
    Top Gainers & Losers·
    US
    PHR
    +1.31%
    US
    GOGO
    -9.91%
    US
    DYN
    -0.77%
    © 2025 Longbridge｜Disclaimer